SEATTLE--(BUSINESS WIRE)--NephroDI Therapeutics (NephroDI), a pharmaceutical company focusing on concentration disorders of the kidney, announces today it has entered an agreement with The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies which identifies and supports early-stage opportunities that can change the landscape of treatments for renal disorders and mental illness.
MSRD at Otsuka in the U.S. and NephroDI will collaborate with respect to the clinical development of NephroDI’s asset, NDI-5001, a novel kidney-targeted small molecule AMPK activator, as a potential therapy for X-linked congenital Nephrogenic Diabetes Insipidus (NDI). NDI is a rare genetic kidney condition that affects individuals from birth, causing them to produce up to 20 liters of urine per day.
Under the terms of the agreement, NephroDI and MSRD will exclusively develop NDI-5001 through completion of certain clinical studies with the opportunity for MSRD to elect to expand the collaboration after those studies or upon the occurrence of certain triggering events. Later studies are anticipated to include affected individuals, providing an opportunity for early evidence of target engagement through increases in urine concentrating ability.
“X-linked NDI pediatric patients and their caregivers currently navigate a lifetime of intense symptom management. There are minimally effective treatments currently available for NDI that do little to significantly improve quality of life for patients and their families,” said Rachael Hagan, CEO of NephroDI. “The NDI, renal, and nephrology experts now collaborating across NephroDI, MSRD, and Otsuka are uniquely positioned to embark on the next phase of development for a potential, novel NDI treatment. This team is driven by the opportunity to bring a first-in-class treatment to these patients and their families.”
About NephroDI Therapeutics
NephroDI Therapeutics, Inc. is a pharmaceutical company headquartered in Seattle, Washington, focused on developing and commercializing a class of novel kidney-targeted AMPK activators which showed promise in modulating urine concentration function in the kidney. The company’s lead program is NDI-5001, a preclinical-stage small molecule being developed for the treatment of NDI. For more information, please visit the company website at www.nephrodi.com.
This press release contains certain “forward-looking statements” concerning the development of NephroDI Therapeutics’ products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions, and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. NephroDI Therapeutics undertakes no obligation to update any forward-looking statements for any reason.